The Two Revolutions in the Treatment of Advanced Non-small Cell Lung Cancer

2016 ◽  
Vol 12 (01) ◽  
pp. 15
Author(s):  
Maurice Pérol ◽  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Personalised Medicine ◽  
Significant Proportion ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Small Cell Lung ◽  
Lung Cancer Patients

In parallel with the evolution of therapeutic paradigms for advanced cancers, treatment of advanced non-small cell lung cancer (NSCLC) has been through the revolution of personalised medicine benefiting for a minority of patients whose disease depends on a single oncogenic genetic alteration targetable by specific tyrosine kinase inhibitors. As well as for some other tumour types, targeting immune checkpoints inhibitors has shown encouraging activity for some patients, suggesting the dawn of a second therapeutic revolution for a significant proportion of lung cancer patients.

Abstract B3: Relevance of genotyping non-small-cell lung cancer patients on response to platinum-basedchemotherapy and tyrosine kinase inhibitors

2012 ◽  
Vol 18 (3 Supplement) ◽  
pp. B3-B3
Author(s):  
Alma D. Campos-Parra ◽  
Graciela Cruz ◽  
Carlos Zuloaga ◽  
Alejandro Aviles ◽  
María E. Vázquez Manríquez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

2016 ◽  
Vol 9 (1) ◽  
pp. 62-67 ◽  
Author(s):  
Corey A. Carter ◽  
Bryan T. Oronsky ◽  
Scott Z. Caroen ◽  
Jan J. Scicinski ◽  
Pedro Cabrales ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Partial Response ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Mutated

RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on sequential or concomitant rechallenge to resistant first- or second-line regimens. One of these trials is designated TRIPLE THREAT (NCT02489903), because it explores the conditioning or priming effect of RRx-001 on three tumor types - non-small cell lung cancer (NSCLC), small cell lung cancer and high-grade neuroendocrine tumors - prior to re-administration of platinum doublets. In follow-up to a recent case study, which describes early monotherapeutic benefit with RRx-001 in a refractory EGFR-mutated NSCLC tumor, we present subsequent evidence of a radiological partial response to reintroduced platinum doublets after RRx-001. For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. A retrial of these therapies in EGFR-positive NSCLC patients via priming with epigenetic agents such as RRx-001 constitutes a strategy to ‘episensitize' tumors (i.e. reverse resistance by epigenetic means) and to extend overall survival.

scholarly journals TYROSINE KINASE INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

2018 ◽  
Vol 23 (1) ◽  
pp. 50-54
Author(s):  
Svetlana Yu. Sletina ◽  
E. V Poddubskaya
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Epidermal Growth

Considering the findings regarding the excellent frequency response (approximately 70%), survival without disease progression (median approximately of 9 months), better safety profile and the superior quality of life for patients compared with standard chemotherapy, EGFR TKIs in EGFR mutation positive non-small cell lung cancer patients can be now considered as first-line treatment in these patients. Evaluation of epidermal growth factor receptor mutations is necessary for all non-small cell lung cancer patients as the effective prognostic marker of the response to tyrosine kinase inhibitors of EGFR.

Sign in / Sign up

Export Citation Format

Share Document